The healthcare industry is extremely complex

due to

  • regulatory issues
  • direct-to-patient marketing and
  • the powerful bond of privacy and trust between providers and patients.
Whether addressing physician or patient, we comprehend the fast changing issues involved in bettering the lives of patients.
 
The upside to better patient care is unlimited.

You know – we know

AMG, AMNOG, ATC, Benefit Assessment of Pharmaceuticals, BfArM, Biologics, Biosimilars, BLA, BMG, Breakthrough Therapy Designation, CHMP, CME, Compassionate Use, Compliance, DocCheck, EC, EMA, EPAR, FDA, G-BA, Generic, HCP, HWG, ICD-10, INN, IQWiG, Labelling, Lay Audience, Leaflet, MAA, MHRA, NCI, NDA, NICE, NIH, NPP (§ 73,3 AMG), NUB, OD, Off-Label-Use, Orphan Drugs, OL, OTC, PBM, PDUFA, PEI, Pharmacovigilance, Positive Opinion, Priority Review Designation, RA, Recombinant, Reference Prices, SGB V, Small Molecule …

OncoBrands on OncoTrends

Abraxane®, Afitinor®, Caprelsa®, Erivedge®, Giotrif®, Halaven®, Inlyta®, Jevtana®, Kadcyla®, Keytruda®, Mekinist®, Neulasta®, Opdivo®, Perjeta®, Stivarga®, Tafinlar®, Vectibix®, Vidaza®, Xalkori®, Xgeva®, Xtandi®, Yervoy®, Zaltrap®, Zelboraf®, Zytiga® ….

Legal: Joachim Freischem & Georg Puluj - Prinzenstr. 12 - D-80639 Munich - Phone: +49/89/1639906-0 - VAT-No.: DE169293019 - info@aeses.de